Influenza surveillance in the Islamic Republic of Iran from 1991 to 2001

T. Mokhtari-Azad,1 H. Mohammadi,1 A. Moosavi,1 Z. Saadatmand1 and R. Nategh1

ABSTRACT To better understand the annual distribution of influenza virus in our country, we isolated and typed 45 viruses from 1043 patients with acute respiratory illnesses in a 10-year study conducted by the National Influenza Centre of the Islamic Republic of Iran. The seasonal distribution of influenza typically ran from November to April. Type A influenza was most common during the winters of 1991–1992, 1997–1998 and 2000–2001 and type B influenza was most common during 1992–1995 and 1996–1997. Both type A and type B viruses circulated in 1995–1996 and 1998–2000. A serological survey based on haemagglutination inhibition test confirmed our findings. The annual pattern of strains isolated was similar to the worldwide pattern during the same interval.

Surveillance de la grippe en République islamique d'Iran de 1991 à 2001


1Department of Virology, School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.

Received: 14/11/2001; accepted 27/06/2002
Introduction

Infection with influenza viruses results in a spectrum of clinical responses ranging from asymptomatic infection to viral pneumonia that can rapidly progress to a fatal outcome [1]. A typical, uncomplicated influenza syndrome is tracheobronchitis with the additional involvement of small airways [2]. Influenza viruses have a major impact on morbidity in hospitalizations. Morbidity has recently been defined in children, in women of all ages with high-risk conditions and in pregnant women [3–5].

Influenza remains an important virological infection that can cause epidemics or pandemics following the emergence of new strains due to drift or shift in viral surface antigens [1,6]. To monitor prevalent strains, the World Health Organization (WHO) maintains a collaborative surveillance network with reference laboratories.

The National Influenza Centre of the Islamic Republic of Iran at the School of Public Health, Tehran University of Medical Sciences, Tehran records the distribution of influenza viruses every year. This includes the isolation and typing of influenza viruses and the estimation of population antibody levels by haemagglutination inhibition (HI) testing against particular strains of influenza viruses in particular years.

The seasonal distribution of influenza in the country is typically from November to April with a peak number of cases recorded in February (Figure 1). To better understand the annual distribution of influenza virus in the country, we conducted virological and serological investigations over a 10-year period beginning with the 1991–92 influenza season and ending in the 2000–01 season.

Methods

Pharyngeal washing and throat swabs from 1043 patients with acute respiratory illness were collected from patients attending clinics in Tehran and from patients in the other provinces (sent to us by the Ministry of Health). These patients had fever, cough, sore throat, general malaise, chills and myalgia. The samples were transported from collection points to our laboratory according to WHO protocols. Viruses were isolated by amniotic and allantoic inoculation into 10–11-day-old embryonated chicken eggs.

Figure 1 Distribution of influenza isolated by month over the period 1991 to 2001

11 Influenza surveillance in the Islamic.pmd 316 6/30/2005, 10:11 AM
and then typed by HI test following WHO protocols [3]. Prototype strains of viruses and antisera were provided by the WHO Collaborating Centre, London, United Kingdom. All viruses were sent to the WHO influenza centres in London or Sydney for further typing and sequencing.

During 1991–2001, a total of 4973 serum samples were collected from among all age groups. Standard microtitre techniques (0.5% hen erythrocytes, 4 units of viruses) were used to detect serum HI antibodies at the dilutions from 1:10 to ≥ 1:640. Unspecific inhibitors were removed by treatment with receptor-destroying enzyme or potassium periodate [3]. The HI antibodies were determined by different strains of influenza A (H1N1), A (H3N2) and B antigens that were prepared from viruses circulating during the particular season.

Results

Figure 1 shows the results of isolation and typing of viruses during 1991–2001. Of 1043 throat samples, 45 influenza viruses were isolated and typed. Most of the isolations were made in winter (Figure 1). Influenza viruses were isolated every year during the 10-year period. Type A (H3N2) viruses were isolated in the winters of 1991–92 and 1997–98. Type B viruses were isolated in the winters of 1992–93, 1993–94, 1994–95 and 1996–97. Both type A (H3N2) and type B viruses were circulating in the winters of 1995–96, 1998–99 and 1999–2000. During the 10-year period influenza type A (H1N1) was isolated only in the winter of 2000–2001. Table 1 shows our national data and WHO international data.

Figures 2 and 3 show the results of the serological survey. The percentages of antibody titre (titre ≥ 40) against influenza type A and B differed during the 10-year period (Figure 2). A greater than 4-fold increase in antibody titre (titre ≥ 1:160) indicated recent infection, suggesting that in recent years both influenza type A and B were circulating, whereas in past years type A was more common (Figure 3).

Discussion

During 1991–2001, the influenza viruses circulating in the Islamic Republic of Iran displayed patterns identical to those seen worldwide (Table 1) [8–17]. Influenza viruses were isolated from all age groups. High fever, chill and myalgia were the predominant signs and symptoms of these patients.

In the winter of 1991–92, the percentage of antibody titre ≥ 1:40 against influenza type B was 3.2%. For the next 5 years, only influenza type B was isolated with the level of HI antibody to type B influenza gradually increasing and reaching its highest level in the winter of 1994–95 (92.0%). Interpretation of prevalence on the basis of laboratory confirmation was difficult due to potential inadequacies in specimen handling, the transit time of the specimens, and the capacity of the laboratory. In the Islamic Republic of Iran, the absence of data on morbidity and mortality from pneumonia makes interpretation even more difficult.

During the 10-year study period, influenza type A (H3N2) was isolated in 1991–92, in 1995–96 and in each of the influenza seasons during the years 1997–2000. However, according to seroepidemiological data, influenza type B was also circulating during this time. Influenza type A (H1N1) was isolated in the winter of 2000–01 (Ta-
The presence of HI antibody with titre $\geq 160$ confirmed the circulation of both type A and type B (Figure 3).

Although it was not a common practice to isolate influenza type C (because of its mild symptoms), for the first time in this laboratory we performed a serum survey on influenza type C. We found that 43.7% of the samples contained antibody titre $\geq 1:40$ against this type with the pattern of seropositivity distribution in different age groups similar to that seen in other countries [18].

<table>
<thead>
<tr>
<th>Influenza season</th>
<th>Strains isolated in Islamic Republic of Iran</th>
<th>Strains isolated worldwide</th>
</tr>
</thead>
<tbody>
<tr>
<td>1991–92</td>
<td>A/Beijing/89 (H3N2) A/Washington/15/91 (H3N2) B/Quingdao/102/91</td>
<td></td>
</tr>
<tr>
<td>1992–93</td>
<td>B/Panama/45/90 A/Beijing/32/92 (H3N2) A/Texas/36/91 (H1N1) B/Quingdao/102/91</td>
<td></td>
</tr>
<tr>
<td>1993–94</td>
<td>B/Panama/45/90 A/Shangdong/9/93 (H3N2) B/Panama/45/90 B/Quingdao/102/91</td>
<td></td>
</tr>
<tr>
<td>1994–95</td>
<td>B/Panama/45/90 A/Johanesburg/33/94 A/Singapore/6/80 (H1N1) A/Texas/36/91 (H1N1) B/Shanghai/4/94</td>
<td></td>
</tr>
<tr>
<td>1995–96</td>
<td>B/Panama/45/90 A/Wuhan/359/95 (H3N2) A/Singapore/6/80 (H1N1) A/Texas/36/9 (H1N1) B/Beijing/184/93 B/Harbin/7/94</td>
<td></td>
</tr>
<tr>
<td>1996–97</td>
<td>B/Beijing/184/93 A/Wuhan/359/95 (H3N2) A/Singapore/6/80 (H1N1) A/Texas/36/9 (H1N1) B/Beijing/184/93 B/Harbin/7/94 B/Guangdong/5/94</td>
<td></td>
</tr>
<tr>
<td>1997–98</td>
<td>A/Nanchang/933/95 (H3N2) A/Wuhan/359/95 (H3N2) B/Beijing/184/93 B/Harbin/7/94 B/Victoria/2/87</td>
<td></td>
</tr>
<tr>
<td>1998–99</td>
<td>A/Sydney/05/97 (H3N2) B/Beijing/184/93 A/Sydney/5/97 A/Wuhan/359/95 B/Beijing/184/93 B/Beijing/243/97</td>
<td></td>
</tr>
<tr>
<td>1999–00</td>
<td>A/Sydney/05/97 (H3N2) B/Yamanashi A/Moscow/10/99 (H3N2) A/Wuhan/262/95 (H1N1) B/Beijing/184/93</td>
<td></td>
</tr>
</tbody>
</table>
Figure 2 Seroepidemiology of influenza A and B during 1991–2001 (positive sera = HI antibody titre ≥ 40)

Figure 3 Distribution of sera with HI antibody titre ≥ 160 to influenza A and B during 1991–2001 (positive sera = HI antibody titre ≥ 160)
The season of maximum distribution of influenza was from November to April with a peak in February (Figure 1). The mild climate of the country might have influenced the incidence of influenza and severity of clinical symptoms. A correlation between influenza activity and climate has previously been suggested for other countries [8].

**Acknowledgement**

This work was supported by grant number 241/70/2 from the School Of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.

**References**


**Intercountry meeting on Emerging Infectious Diseases (EID)**

The World Health Organization Regional Office for the Eastern Mediterranean convened the above-mentioned meeting in Beirut, Lebanon from 6 to 8 April 2004. The objectives of the meeting were:

- To promote communicable diseases surveillance and response activities for EID in the Eastern Mediterranean countries;
- To share experiences of Member States in combatting EID that occurred in 2003;
- To identify emerging health risks and develop plans of concerted efforts to control EID in Member States.

Directors of communicable disease programmes from all EMR Member States were invited to participate in the meeting. Representatives from nongovernmental organizations, UN organizations and other concerned partners, and staff members from WHO/HQ were also invited to attend.